SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Lorraine Hansberry Synthetic CCD

PatientLorraine Hansberry
Date of birth1993-05-19
IdentifiersMRN HR-ML034-SYN; SSN (made up) 000-34-7158
Document date2026-11-01
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CT. Concerns: Burning, boring pain under the breastbone and through to the back for about two months, worse after meals and at night; black stools on and off for three weeks; two near-fainting spells; weight down 5 kg; An urgent care clinic put the pain down to indigestion and stress five weeks ago; she does not want it put down to stress again, and wants the cause found and told to her plainly, whatever it is; She wants to finish her play and to keep writing through whatever treatment she needs, with a clear head. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route2026-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route2026-04-24 to 2026-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route2026-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route2026-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route2026-05-04 to 2026-10-05completedS
Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-27completedS
Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5Day 1 every 14 days, cycles 1 to 5Intravenous route2026-05-18 to 2026-07-13completedS
Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6Day 1 of cycle 6Intravenous route2026-07-27 to 2026-07-27completedS
Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-27completedS
Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus46-hour infusion from day 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-29completedS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected6 mg on day 3 of each cycleSubcutaneous route2026-05-20 to 2026-07-29completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route2026-05-18activeS
Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycleOne tablet at night on days 1 to 4Oral route2026-05-18activeS
Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed4 mg at onset, then 2 mg after each loose stoolOral route2026-05-18activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgeryOne tablet twice dailyOral route2026-06-29 to 2026-08-21completedS
Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days40 mEq today, then 20 mEq daily for three daysOral route2026-07-16 to 2026-07-19completedS
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg once daily for 28 daysSubcutaneous route2026-08-24 to 2026-09-21completedS
Insulin glargine 100 units/mL pen, 8 units under the skin at night8 units at nightSubcutaneous route2026-08-28 to 2026-10-05completedS
Insulin glargine 100 units/mL pen, 10 units under the skin at night10 units at nightSubcutaneous route2026-10-05activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snackThree capsules with each meal, two with each snackOral route2026-10-05activeS
Irinotecan 20 mg/mL injection, 184 mg (120 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgeryDay 1 every 14 days for six cyclesIntravenous route2026-10-12activeS
Leucovorin 10 mg/mL injection, 612 mg (400 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgeryDay 1 every 14 days for six cyclesIntravenous route2026-10-12activeS
Fluorouracil 50 mg/mL injection, 3670 mg (2400 mg/m2) by continuous infusion over 46 hours from day 1 of each 14-day cycle, for six cycles after surgery46-hour infusion from day 1 every 14 days for six cyclesIntravenous route2026-10-12activeS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle after surgery6 mg on day 3 of each cycleSubcutaneous route2026-10-14activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy after surgeryOne tablet twice dailyOral route2026-10-12activeS

Procedures

ProcedureDatesStatusEvidence
Upper endoscopy with biopsy, under sedation: no gastric or duodenal ulcer; a friable, ulcerated mass on the medial wall of the second part of the duodenum next to the major papilla, oozing slowly; four biopsies taken; hemostasis with epinephrine injection2026-04-22 to 2026-04-22completedS
Pancreas-protocol CT of the abdomen and pelvis with contrast (arterial and portal venous phases), with CT of the chest: a 3.1 cm hypoattenuating mass in the head of the pancreas invading the duodenal wall; dilated common bile duct (13 mm) and pancreatic duct (5 mm); tumor contact with about 200 degrees of the superior mesenteric vein with short-segment narrowing that can be reconstructed; no contact with the superior mesenteric artery, celiac axis or common hepatic artery; no liver, peritoneal or lung lesion; no ascites2026-04-23 to 2026-04-23completedS
Endoscopic ultrasound with fine-needle biopsy of the pancreatic head mass (three passes with a 22-gauge biopsy needle): 3.2 cm hypoechoic mass invading the duodenum and abutting the portal confluence; no ascites; rapid on-site evaluation adequate; extra cores sent for tumor molecular profiling2026-04-27 to 2026-04-27completedS
ERCP in the same session with placement of a fully covered self-expanding metal stent (10 mm by 60 mm) across a distal common bile duct stricture; good drainage of bile2026-04-27 to 2026-04-27completedS
Pancreatic multidisciplinary tumor board (surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, pathology, palliative care, nurse navigator): borderline resectable pancreatic head adenocarcinoma (venous involvement); recommends chemotherapy before surgery with modified FOLFIRINOX, restaging, then resection if there is no progression2026-04-29 to 2026-04-29completedS
Advance care planning conversation, about 30 minutes2026-10-21 to 2026-10-21completedS
Genetic counseling before germline testing: three-generation pedigree, consent, and explanation of what a positive or negative result would mean for her and her blood relatives2026-05-04 to 2026-05-04completedS
Outpatient palliative care consultation, two days after the diagnosis visit: symptom review, a serious illness conversation about her hopes, worries and what matters most (her writing and a clear head), and a plan for pain, appetite and sleep alongside cancer treatment2026-05-06 to 2026-05-06completedS
Restaging pancreas-protocol CT of the abdomen and pelvis with contrast, with CT of the chest, after six cycles: pancreatic head mass smaller (2.1 cm from 3.1 cm); contact with the superior mesenteric vein reduced to about 150 degrees; no arterial contact; biliary stent in place; no liver, peritoneal or lung lesion2026-08-06 to 2026-08-06completedS
Open pylorus-preserving pancreaticoduodenectomy with segmental resection of the superior mesenteric vein and primary venous repair, and removal of the biliary stent: pathology ypT2N1 (2.3 cm residual adenocarcinoma; 2 of 18 lymph nodes involved; perineural invasion), all margins clear (R0), partial treatment response (CAP tumor regression score 2); nine days in hospital, with mild delayed gastric emptying that settled2026-08-24 to 2026-08-24completedS

Immunizations

DateVaccineStatusEvidence
2022-09-12Tdap vaccinecompletedS
2026-05-04Pneumococcal conjugate vaccine (PCV20), before chemotherapycompletedS
2026-05-04Recombinant zoster vaccine, dose 1 of 2, before chemotherapycompletedS
2026-06-29Recombinant zoster vaccine, dose 2 of 2completedS
2026-10-21Influenza vaccine, this season (inactivated)completedS
2026-10-21COVID-19 mRNA vaccine, this season's formulacompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

RelativeConditionAge at deathEvidence
fatherDied suddenly of a cerebral hemorrhage when she was sixteen; no cancer recorded in the cited sourceD (CLM-0003)

Health Concerns

ConcernStatusEvidence
Burning, boring pain under the breastbone and through to the back for about two months, worse after meals and at night; black stools on and off for three weeks; two near-fainting spells; weight down 5 kgactiveS
An urgent care clinic put the pain down to indigestion and stress five weeks ago; she does not want it put down to stress again, and wants the cause found and told to her plainly, whatever it isactiveS
She wants to finish her play and to keep writing through whatever treatment she needs, with a clear headactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 10.6 on 2026-10-05; MCV [Entitic mean volume] in Red Blood Cells by Automated count 74 on 2026-04-20; Leukocytes [#/volume] in Blood by Automated count 8.2 on 2026-10-05; Platelets [#/volume] in Blood by Automated count 302 on 2026-10-05; Ferritin [Mass/volume] in Serum or Plasma 88 on 2026-06-29; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-10-05; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-10-05; Creatinine [Mass/volume] in Serum or Plasma 0.71 on 2026-10-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 116 on 2026-10-05; Glucose [Mass/volume] in Serum or Plasma 156 on 2026-10-05; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-10-05; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-10-05; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 110 on 2026-10-05; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-10-05; Albumin [Mass/volume] in Serum or Plasma 3.4 on 2026-10-05; Lipase [Enzymatic activity/volume] in Serum or Plasma 52 on 2026-04-20; Hemoglobin A1c/Hemoglobin.total in Blood 7 on 2026-08-10; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-04-20; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 2026-10-05; Neutrophils [#/volume] in Blood by Automated count 5.1 on 2026-10-05; Cancer Ag 19-9 [Units/volume] in Serum or Plasma 18 on 2026-10-05; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 3.9 on 2026-05-04; INR in Platelet poor plasma by Coagulation assay 1 on 2026-08-10; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 2026-10-21; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 on 2026-10-05; Magnesium [Mass/volume] in Serum or Plasma 1.6 on 2026-07-16; Albumin/Creatinine [Mass Ratio] in Urine 12 on 2026-10-05 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPresolvedconfirmed K83.1S — Synthetic consequence of the synthetic tumor.
Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolvedresolvedconfirmed K52.1S — Synthetic treatment effect; not a historical claim.
Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttonsactiveconfirmed G62.0S — Synthetic common effect of oxaliplatin.
After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetesactiveconfirmed Z90.411S — Synthetic consequence of the synthetic operation.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-20Hemoglobin [Mass/volume] in Blood9.1g/dL12-15.5 g/dLLowS
2026-04-20MCV [Entitic mean volume] in Red Blood Cells by Automated count74fL80-100 fLLowS
2026-04-20Leukocytes [#/volume] in Blood by Automated count7.410*3/uL4-11 10*3/uLNormalS
2026-04-20Platelets [#/volume] in Blood by Automated count38810*3/uL150-400 10*3/uLNormalS
2026-04-20Ferritin [Mass/volume] in Serum or Plasma6ng/mL15-150 ng/mLLowS
2026-04-20Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-04-20Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-04-20Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.59-1.04 mg/dLNormalS
2026-04-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M118mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-20Glucose [Mass/volume] in Serum or Plasma132mg/dL70-99 mg/dLHighS
2026-04-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma48U/L7-35 U/LHighS
2026-04-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L8-35 U/LHighS
2026-04-20Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma236U/L35-104 U/LHighS
2026-04-20Bilirubin.total [Mass/volume] in Serum or Plasma1.6mg/dL0.1-1.2 mg/dLHighS
2026-04-20Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
2026-04-20Lipase [Enzymatic activity/volume] in Serum or Plasma52U/L13-60 U/LNormalS
2026-04-20Hemoglobin A1c/Hemoglobin.total in Blood6.6%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
2026-04-20Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-04-20Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S
2026-05-04Hemoglobin [Mass/volume] in Blood10.4g/dL12-15.5 g/dLLowS
2026-05-04Leukocytes [#/volume] in Blood by Automated count710*3/uL4-11 10*3/uLNormalS
2026-05-04Neutrophils [#/volume] in Blood by Automated count4.610*3/uL1.5-7.7 10*3/uLNormalS
2026-05-04Platelets [#/volume] in Blood by Automated count36610*3/uL150-400 10*3/uLNormalS
2026-05-04Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
2026-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M119mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-04Glucose [Mass/volume] in Serum or Plasma141mg/dL70-99 mg/dLHighS
2026-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-35 U/LNormalS
2026-05-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L8-35 U/LNormalS
2026-05-04Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma168U/L35-104 U/LHighS
2026-05-04Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.1-1.2 mg/dLNormalS
2026-05-04Albumin [Mass/volume] in Serum or Plasma3.5g/dL3.5-5 g/dLNormalS
2026-05-04Cancer Ag 19-9 [Units/volume] in Serum or Plasma486U/mL<=35 U/mLHighS
2026-05-04Carcinoembryonic Ag [Mass/volume] in Serum or Plasma3.9ng/mLUp to 3.0 ng/mL in non-smokersHighS
2026-05-04INR in Platelet poor plasma by Coagulation assay1{INR}0.8-1.2NormalS
2026-05-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-05-04Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
2026-05-04Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S
2026-06-29Hemoglobin [Mass/volume] in Blood11.2g/dL12-15.5 g/dLLowS
2026-06-29Leukocytes [#/volume] in Blood by Automated count8.910*3/uL4-11 10*3/uLNormalS
2026-06-29Neutrophils [#/volume] in Blood by Automated count5.810*3/uL1.5-7.7 10*3/uLNormalS
2026-06-29Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2026-06-29Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.59-1.04 mg/dLNormalS
2026-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M114mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-29Glucose [Mass/volume] in Serum or Plasma128mg/dL70-99 mg/dLHighS
2026-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
2026-06-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-35 U/LNormalS
2026-06-29Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma120U/L35-104 U/LHighS
2026-06-29Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-06-29Albumin [Mass/volume] in Serum or Plasma3.5g/dL3.5-5 g/dLNormalS
2026-06-29Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.2 mg/dLNormalS
2026-06-29Ferritin [Mass/volume] in Serum or Plasma88ng/mL15-150 ng/mLNormalS
2026-06-29Cancer Ag 19-9 [Units/volume] in Serum or Plasma210U/mL<=35 U/mLHighS
2026-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
2026-06-29Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]9{score}S
2026-06-29Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
2026-07-16Hemoglobin [Mass/volume] in Blood11g/dL12-15.5 g/dLLowS
2026-07-16Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
2026-07-16Neutrophils [#/volume] in Blood by Automated count4.110*3/uL1.5-7.7 10*3/uLNormalS
2026-07-16Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
2026-07-16Sodium [Moles/volume] in Serum or Plasma134mmol/L135-145 mmol/LLowS
2026-07-16Potassium [Moles/volume] in Serum or Plasma3.2mmol/L3.5-5.1 mmol/LLowS
2026-07-16Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.59-1.04 mg/dLNormalS
2026-07-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-16Glucose [Mass/volume] in Serum or Plasma118mg/dL70-99 mg/dLHighS
2026-07-16Magnesium [Mass/volume] in Serum or Plasma1.6mg/dL1.7-2.2 mg/dLLowS
2026-08-10Hemoglobin [Mass/volume] in Blood10.9g/dL12-15.5 g/dLLowS
2026-08-10Leukocytes [#/volume] in Blood by Automated count7.810*3/uL4-11 10*3/uLNormalS
2026-08-10Neutrophils [#/volume] in Blood by Automated count4.910*3/uL1.5-7.7 10*3/uLNormalS
2026-08-10Platelets [#/volume] in Blood by Automated count17610*3/uL150-400 10*3/uLNormalS
2026-08-10Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-08-10Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-08-10Creatinine [Mass/volume] in Serum or Plasma0.76mg/dL0.59-1.04 mg/dLNormalS
2026-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M107mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-10Glucose [Mass/volume] in Serum or Plasma124mg/dL70-99 mg/dLHighS
2026-08-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-08-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-35 U/LNormalS
2026-08-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma98U/L35-104 U/LNormalS
2026-08-10Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-08-10Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
2026-08-10Hemoglobin A1c/Hemoglobin.total in Blood7%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
2026-08-10Cancer Ag 19-9 [Units/volume] in Serum or Plasma41U/mL<=35 U/mLHighS
2026-08-10INR in Platelet poor plasma by Coagulation assay1{INR}0.8-1.2NormalS
2026-08-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-08-10Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S
2026-10-05Hemoglobin [Mass/volume] in Blood10.6g/dL12-15.5 g/dLLowS
2026-10-05Leukocytes [#/volume] in Blood by Automated count8.210*3/uL4-11 10*3/uLNormalS
2026-10-05Neutrophils [#/volume] in Blood by Automated count5.110*3/uL1.5-7.7 10*3/uLNormalS
2026-10-05Platelets [#/volume] in Blood by Automated count30210*3/uL150-400 10*3/uLNormalS
2026-10-05Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-10-05Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-10-05Creatinine [Mass/volume] in Serum or Plasma0.71mg/dL0.59-1.04 mg/dLNormalS
2026-10-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M116mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-05Glucose [Mass/volume] in Serum or Plasma156mg/dL70-99 mg/dLHighS
2026-10-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-10-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-35 U/LNormalS
2026-10-05Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma110U/L35-104 U/LHighS
2026-10-05Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-10-05Albumin [Mass/volume] in Serum or Plasma3.4g/dL3.5-5 g/dLLowS
2026-10-05Cancer Ag 19-9 [Units/volume] in Serum or Plasma18U/mL<=35 U/mLNormalS
2026-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-10-05Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
2026-10-05Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
2026-10-21Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-10-05Albumin/Creatinine [Mass Ratio] in Urine12mg/g<=30 mg/gNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-20Body height163cmS
2026-04-20Body weight56.2kgS
2026-04-20Body mass index (BMI) [Ratio]21.2kg/m2S
2026-04-20Systolic blood pressure104mm[Hg]S
2026-04-20Diastolic blood pressure66mm[Hg]S
2026-04-20Heart rate102/minS
2026-04-20Respiratory rate16/minS
2026-04-20Body temperature36.8CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-05-04Body height163cmS
2026-05-04Body weight55.4kgS
2026-05-04Body mass index (BMI) [Ratio]20.9kg/m2S
2026-05-04Systolic blood pressure108mm[Hg]S
2026-05-04Diastolic blood pressure68mm[Hg]S
2026-05-04Heart rate92/minS
2026-05-04Respiratory rate16/minS
2026-05-04Body temperature36.7CelS
2026-05-04Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-29Body height163cmS
2026-06-29Body weight54.8kgS
2026-06-29Body mass index (BMI) [Ratio]20.6kg/m2S
2026-06-29Systolic blood pressure110mm[Hg]S
2026-06-29Diastolic blood pressure70mm[Hg]S
2026-06-29Heart rate84/minS
2026-06-29Respiratory rate16/minS
2026-06-29Body temperature36.6CelS
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-08-10Body height163cmS
2026-08-10Body weight54.2kgS
2026-08-10Body mass index (BMI) [Ratio]20.4kg/m2S
2026-08-10Systolic blood pressure112mm[Hg]S
2026-08-10Diastolic blood pressure72mm[Hg]S
2026-08-10Heart rate80/minS
2026-08-10Respiratory rate16/minS
2026-08-10Body temperature36.6CelS
2026-08-10Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-05Body height163cmS
2026-10-05Body weight51.8kgS
2026-10-05Body mass index (BMI) [Ratio]19.5kg/m2S
2026-10-05Systolic blood pressure106mm[Hg]S
2026-10-05Diastolic blood pressure68mm[Hg]S
2026-10-05Heart rate86/minS
2026-10-05Respiratory rate16/minS
2026-10-05Body temperature36.7CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-16Body height163cmS
2026-07-16Body weight53.6kgS
2026-07-16Body mass index (BMI) [Ratio]20.2kg/m2S
2026-07-16Systolic blood pressure98mm[Hg]S
2026-07-16Diastolic blood pressure62mm[Hg]S
2026-07-16Heart rate104/minS
2026-07-16Respiratory rate16/minS
2026-07-16Body temperature37.1CelS
2026-07-16Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-21Body height163cmS
2026-10-21Body weight52.4kgS
2026-10-21Body mass index (BMI) [Ratio]19.7kg/m2S
2026-10-21Systolic blood pressure106mm[Hg]S
2026-10-21Diastolic blood pressure66mm[Hg]S
2026-10-21Heart rate84/minS
2026-10-21Respiratory rate14/minS
2026-10-21Body temperature36.6CelS
2026-10-21Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-04-20Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CTfinishedS
2026-05-04Diagnosis of pancreatic adenocarcinoma: tumor board plan, medical oncology consultation, genetic counseling, early palliative care, and planning of chemotherapy before surgeryfinishedS
2026-06-29Day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and moodfinishedS
2026-08-10After six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomyfinishedS
2026-10-05Six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgeryfinishedS
2026-07-16Same-day sick visit for diarrhea during chemotherapyfinishedS
2026-10-21Periodic adult preventive visit during chemotherapy after surgeryfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Medical oncology consultation within two weeks to review the endoscopy, CT and any biopsy with her and plan treatment if cancer is foundcompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016S
Urgent work-up of epigastric pain with weight loss, anemia and new diabetes: upper endoscopy within days, pancreas-protocol CT of the abdomen with CT of the chest, blood count, ferritin, liver tests, lipase and A1c; pantoprazole until the endoscopy; return at once for fresh black stools, fainting or yellow eyescompletedGL-NCCN-PANC-2026, GL-NOEL-2019S
Intravenous iron for iron deficiency anemia from blood loss, with a blood count at each visitcompletedGL-NCCN-PANC-2026S
Tissue and staging: EUS-guided biopsy with extra cores for molecular profiling, biliary drainage with a metal stent, CA 19-9 after the bilirubin is normal, and review at the pancreatic tumor boardcompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016S
Germline genetic testing with counseling for every patient with pancreatic cancer, and tumor molecular profiling (including KRAS, BRCA1, BRCA2, PALB2, mismatch repair, NTRK and NRG1); cascade testing offered to blood relatives only if a germline variant is foundcompletedGL-NCCN-PANC-2026, GL-ASCO-PANCGERM-2019, GL-ASCO-MPC-2020S
Modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 over 46 hours) every two weeks for six cycles (three months) before surgery through a port, with pegfilgrastim, olanzapine-based antiemetic prevention that spares dexamethasone because of her diabetes, loperamide for late diarrhea, and neuropathy checks; CA 19-9 every two cycles and restaging CT after four and six cycles; hepatitis B, hepatitis C and HIV screening and a pregnancy test firstcompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020S
Palliative care from the day of diagnosis, alongside cancer treatment: symptom control, a serious illness conversation, and planning that keeps her writing at the center; oxycodone 5 mg as needed with a bowel regimen, and EUS-guided celiac plexus neurolysis if pain becomes severecompletedGL-ASCO-PALL-2024, GL-NCCN-PANC-2026S
Nutrition: dietitian review at each phase, pancrelipase with every meal and snack, small frequent meals, weight at every visitcompletedGL-NCCN-PANC-2026S
Diabetes due to pancreatic disease: home glucose checks, A1c every three months, glucose checks before each cycle; insulin rather than oral agents if treatment is needed after surgery; dilated eye examination and urine albumin-to-creatinine ratio at diagnosiscompletedGL-ADA-2026, GL-CMID-2026S
Venous thromboembolism: Khorana score recorded (3: pancreatic primary and hemoglobin below 10 g/dL); prophylactic apixaban offered once the duodenal bleeding has settled; enoxaparin for four weeks after surgerycompletedGL-ASCO-VTE-2023, GL-AVERT-2019S
Fertility and contraception: oncofertility counseling before chemotherapy, a pregnancy test before treatment, and effective non-estrogen contraception if she becomes sexually active during treatmentcompletedGL-ASCO-FERT-2018S
Pylorus-preserving pancreaticoduodenectomy with resection of the involved segment of the superior mesenteric vein after restaging shows no progressioncompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016S
Chemotherapy after surgery to complete about six months of treatment: six cycles of fluorouracil, leucovorin and irinotecan every two weeks, without oxaliplatin because of neuropathy; insulin glargine adjusted to home glucose readings; apixaban prophylaxis resumed during chemotherapy; surveillance afterwards with history, examination, CA 19-9 and CT every three to six months for two yearscompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-VTE-2023S
Distress and depression screening at each visit, plain explanations with written information, and support she chooses; she decides who is told and who receives each notecompletedGL-USPSTF-DEP-2023, GL-ASCO-PALL-2024S

Goals

GoalTargetStatusOutcomeProvenance
Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation2026-05-04completedEndoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeksS
Germline genetic testing with counseling and tumor molecular profiling resulted before surgery2026-06-29completedGermline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alterationS
Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week2026-08-10completedSix cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial responseS
Resection with clear margins if restaging shows no progression2026-10-05completedPancreaticoduodenectomy with vein resection; margins clear (R0)S
Pain 3 out of 10 or less with a clear head for writing2026-06-29completedPain 1 to 2 out of 10 on oxycodone 5 mg once or twice a dayS
Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support2026-08-10completedWeight 54.2 kg before surgery, 2 percent below the weight at diagnosisS
PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment2026-10-05completedPHQ-9 between 6 and 8S

Functional Status

Mental Status